Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03527108
Title Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + Ramucirumab

Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.